BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 16154719)

  • 1. Prolonged exposure to the candidate microbicide C31G differentially reduces cellular sensitivity to agent re-exposure.
    Catalone BJ; Ferguson ML; Miller SR; Malamud D; Kish-Catalone T; Thakkar NJ; Krebs FC; Howett MK; Wigdahl B
    Biomed Pharmacother; 2005 Sep; 59(8):460-8. PubMed ID: 16154719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxicity, inflammation, and anti-human immunodeficiency virus type 1 activity following exposure to chemical moieties of C31G.
    Catalone BJ; Miller SR; Ferguson ML; Malamud D; Kish-Catalone T; Thakkar NJ; Krebs FC; Howett MK; Wigdahl B
    Biomed Pharmacother; 2005 Sep; 59(8):430-7. PubMed ID: 16154721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactivation of human immunodeficiency virus type 1 by nonoxynol-9, C31G, or an alkyl sulfate, sodium dodecyl sulfate.
    Krebs FC; Miller SR; Malamud D; Howett MK; Wigdahl B
    Antiviral Res; 1999 Oct; 43(3):157-73. PubMed ID: 10551374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium dodecyl sulfate and C31G as microbicidal alternatives to nonoxynol 9: comparative sensitivity of primary human vaginal keratinocytes.
    Krebs FC; Miller SR; Catalone BJ; Welsh PA; Malamud D; Howett MK; Wigdahl B
    Antimicrob Agents Chemother; 2000 Jul; 44(7):1954-60. PubMed ID: 10858360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative in vitro sensitivities of human immune cell lines, vaginal and cervical epithelial cell lines, and primary cells to candidate microbicides nonoxynol 9, C31G, and sodium dodecyl sulfate.
    Krebs FC; Miller SR; Catalone BJ; Fichorova R; Anderson D; Malamud D; Howett MK; Wigdahl B
    Antimicrob Agents Chemother; 2002 Jul; 46(7):2292-8. PubMed ID: 12069993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of the anti-microbial agent C31G as a spermicide: comparison with nonoxynol-9.
    Thompson KA; Malamud D; Storey BT
    Contraception; 1996 May; 53(5):313-8. PubMed ID: 8724622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized Phase I vaginal safety study of three concentrations of C31G vs. Extra Strength Gynol II.
    Mauck CK; Weiner DH; Creinin MD; Barnhart KT; Callahan MM; Bax R
    Contraception; 2004 Sep; 70(3):233-40. PubMed ID: 15325893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative safety evaluation of the candidate vaginal microbicide C31G.
    Catalone BJ; Kish-Catalone TM; Neely EB; Budgeon LR; Ferguson ML; Stiller C; Miller SR; Malamud D; Krebs FC; Howett MK; Wigdahl B
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1509-20. PubMed ID: 15793133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A non-antibiotic antimicrobial mixture (C31G): evaluation of the antimicrobial efficiency of C31G on vaginal cultures.
    Calis S; Yulug N; Sumnu M; Ayhan A; Hincal AA
    Boll Chim Farm; 1992 Oct; 131(9):335-8. PubMed ID: 1492969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of suppository bases on the release properties of a potent antimicrobial agent (C31G).
    Caliş S; Sumnu M; Hincal AA
    Pharmazie; 1994 May; 49(5):336-9. PubMed ID: 8016179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mice and rabbit models for oral and percutaneous absorption and disposition of amphoteric surfactant C31G.
    Michaels EB; Hahn EC; Kenyon AJ
    Am J Vet Res; 1983 Oct; 44(10):1977-83. PubMed ID: 6638657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical study of a C31G containing mouthrinse: effect on salivary microorganisms.
    Corner AM; Brightman VJ; Cooper S; Yankell SL; Malamud D
    J Clin Dent; 1990; 2(2):34-8. PubMed ID: 2090157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of C31G, an antimicrobial surfactant, on healing of incised guinea pig wounds.
    Michaels EB; Hahn EC; Kenyon AJ
    Am J Vet Res; 1983 Jul; 44(7):1378-81. PubMed ID: 6881675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I comparative postcoital testing study of three concentrations of C31G.
    Mauck CK; Creinin MD; Barnhart KT; Ballagh SA; Archer DF; Callahan MM; Schmitz SW; Bax R
    Contraception; 2004 Sep; 70(3):227-31. PubMed ID: 15325892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Male tolerance study of 1% C31G.
    Mauck CK; Frezieres RG; Walsh TL; Schmitz SW; Callahan MM; Bax R
    Contraception; 2004 Sep; 70(3):221-5. PubMed ID: 15325891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The microbicidal agent C31G inhibits Chlamydia trachomatis infectivity in vitro.
    Wyrick PB; Knight ST; Gerbig DG; Raulston JE; Davis CH; Paul TR; Malamud D
    Antimicrob Agents Chemother; 1997 Jun; 41(6):1335-44. PubMed ID: 9174195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the interfacial properties of a new potent antimicrobial surfactant C31G.
    Unlü N; Caliş S; Sumnu M; Hincal AA
    Boll Chim Farm; 1991 Jun; 130(6):234-8. PubMed ID: 1756007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controlled wound repair in guinea pigs, using antimicrobials that alter fibroplasia.
    Kenyon AJ; Hamilton SG; Douglas DM
    Am J Vet Res; 1986 Jan; 47(1):96-101. PubMed ID: 3946914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C31G, a new agent for oral use with potent antimicrobial and antiadherence properties.
    Corner AM; Dolan MM; Yankell SL; Malamud D
    Antimicrob Agents Chemother; 1988 Mar; 32(3):350-3. PubMed ID: 3364952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surfactant and UV-B-induced damage of the cultured bovine lens.
    Youn HY; Moran KL; Oriowo OM; Bols NC; Sivak JG
    Toxicol In Vitro; 2004 Dec; 18(6):841-52. PubMed ID: 15465651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.